Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2026)
Inhibikase Therapeutics (IKT) reported Return on Capital Employed of 32.19% for Q1 2026, up 1151.0% year-over-year from 2.57% in Q1 2025, and up 24.39% quarter-over-quarter from 42.57% in Q4 2025.
Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has 6 years of Return on Capital Employed data on file, last reported at 32.19% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 32.19%, up 1151.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 32.19% (up 1151.0% YoY), and the FY2025 annual result was 39.49%, up 1463.0% from the prior year.
- Return on Capital Employed improved to 32.19% in Q1 2026 per IKT's latest filing, from 42.57% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 32.19% in Q1 2026 and troughed at 1184.15% in Q3 2024.
- A 5-year average of 173.62% and a median of 76.21% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 106890 bps in 2024, then jumped 111821 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 78.6% in 2022, then sank by 100 bps to 157.5% in 2023, then jumped by 62 bps to 59.87% in 2024, then grew by 29 bps to 42.57% in 2025, then increased by 24 bps to 32.19% in 2026.
- Business Quant data shows IKT's Return on Capital Employed at 32.19% in Q1 2026, 42.57% in Q4 2025, and 65.95% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Inhibikase Therapeutics | 285.17 Mn | 114.80 Mn | - | -32.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.19% |
| Dec 31, 2025 | -42.57% |
| Sep 30, 2025 | -65.95% |
| Jun 30, 2025 | -53.39% |
| Mar 31, 2025 | -43.70% |
| Dec 31, 2024 | -59.87% |
| Sep 30, 2024 | -1,184.15% |
| Jun 30, 2024 | -304.43% |
| Mar 31, 2024 | -235.64% |
| Dec 31, 2023 | -157.50% |
| Sep 30, 2023 | -115.25% |
| Jun 30, 2023 | -87.76% |
| Mar 31, 2023 | -76.21% |
| Dec 31, 2022 | -78.60% |
| Sep 30, 2022 | -67.09% |
| Dec 31, 2021 | -36.81% |
| Sep 30, 2021 | -24.37% |
| Jun 30, 2021 | -24.86% |
| Mar 31, 2021 | -50.35% |